IMMUNOHISTOCHEMISTRY PANEL (7-IHC) at Test Zone Diagnostic Center

Introduction to the IMMUNOHISTOCHEMISTRY PANEL (7-IHC) at Test Zone Diagnostic Center

The IMMUNOHISTOCHEMISTRY PANEL (7-IHC) at Test Zone Diagnostic Center is a highly specialized, state-of-the-art pathology investigation designed to characterize cellular proteins within tissue specimens. Immunohistochemistry (IHC) represents the intersection of immunology, histology, and molecular biology. By utilizing specific monoclonal and polyclonal antibodies that bind to target antigens within a tissue sample, this panel allows consultant pathologists to visualize the precise localization, distribution, and abundance of diagnostic biomarkers under a light microscope. Unlike standard histopathological staining, such as Hematoxylin and Eosin (H&E), which primarily highlights cellular morphology, the 7-IHC panel provides a deep functional and molecular profile of the tissue. This diagnostic depth is essential for differentiating benign from malignant lesions, identifying the primary origin of metastatic tumors, subtyping hematological malignancies, and determining the expression of therapeutic targets in oncological cases.

The clinical utility of a seven-antibody panel lies in its ability to simultaneously evaluate multiple diagnostic pathways. In complex oncological scenarios, a single marker is rarely sufficient to establish a definitive diagnosis due to overlapping morphological features among different tumor lineages. By selecting a customized panel of seven distinct antibodies, pathologists can systematically rule in or rule out specific diagnostic possibilities. For instance, a 7-IHC panel can differentiate between epithelial, mesenchymal, melanocytic, and lymphoid lineages in poorly differentiated neoplasms. The technology utilizes enzyme-labeled antibodies (typically conjugated with horseradish peroxidase or alkaline phosphatase) that react with a chromogenic substrate, such as diaminobenzidine (DAB), to produce a visible, colored precipitate at the site of antigen-antibody binding. This precise localization allows for both qualitative and semi-quantitative assessment of protein expression, which directly influences therapeutic decisions, prognostic stratifications, and personalized patient management plans.

Clinical Procedure: What to Expect

Patient Preparation

Because the IMMUNOHISTOCHEMISTRY PANEL (7-IHC) at Test Zone Diagnostic Center is performed on tissue specimens that have already been extracted from the patient, there is no direct physical preparation required for the laboratory phase of the test. However, the preparation depends entirely on the clinical procedure used to obtain the tissue specimen. If the tissue is to be obtained via a fine-needle aspiration biopsy (FNAB), core needle biopsy, or surgical excision, patients must follow specific instructions provided by their referring physician or interventional radiologist. This may include fasting for a specific number of hours if conscious sedation or general anesthesia is required, temporarily discontinuing blood-thinning medications under medical supervision to minimize bleeding risks, and arranging for post-procedure transportation. If the patient is submitting an existing formalin-fixed paraffin-embedded (FFPE) tissue block or pre-cut unstained slides obtained from another facility, they must ensure the specimen is accompanied by the original histopathology report and is transported at room temperature in secure, protective packaging.

During the Procedure

The laboratory phase of the IMMUNOHISTOCHEMISTRY PANEL (7-IHC) at Test Zone Diagnostic Center follows a rigorous, multi-step protocol to ensure analytical precision and reproducibility. Once the tissue specimen is received, it undergoes formal histopathological processing. The tissue is fixed in 10% neutral buffered formalin to preserve cellular architecture and prevent autolysis. It is then dehydrated, cleared, and embedded in paraffin wax to create an FFPE block. Ultra-thin sections, typically measuring 3 to 5 micrometers, are cut using a high-precision microtome and mounted onto specialized, positively charged glass slides to prevent tissue detachment during subsequent wash cycles.

The staining process begins with deparaffinization and rehydration of the tissue sections. Because formalin fixation causes protein cross-linking that can mask antigenic sites, the slides undergo antigen retrieval. This is achieved using heat-induced epitope retrieval (HIER) in a pH-controlled buffer solution or enzymatic epitope retrieval (EER). Once the target epitopes are exposed, the slides are incubated with the primary antibodies. After thorough washing to remove unbound antibodies, a secondary detection system is applied, which typically consists of a biotinylated secondary antibody or a polymer-based detection system linked to an enzyme. The addition of a chromogen substrate produces a highly visible brown or red precipitate at the target site. Finally, the slides are counterstained with hematoxylin to visualize cellular nuclei, dehydrated, cleared, and coverslipped. A consultant pathologist then examines the slides under a high-resolution light microscope, evaluating the percentage of positive cells, the intensity of the staining, and the subcellular localization (nuclear, cytoplasmic, or membranous) of each of the seven markers.

When is a IMMUNOHISTOCHEMISTRY PANEL (7-IHC) Performed?

Characterization of Undifferentiated Tumors

Physicians request a 7-IHC panel when a routine tissue biopsy reveals a highly malignant, poorly differentiated, or undifferentiated neoplasm that cannot be classified by cellular morphology alone. When cells lose their mature characteristics, they often look identical under standard H&E staining, regardless of their tissue of origin. The 7-IHC panel assists the pathologist in determining whether the tumor is a carcinoma (epithelial origin), sarcoma (mesenchymal origin), lymphoma (hematopoietic origin), or melanoma (melanocytic origin) by evaluating lineage-specific markers.

Subtyping of Lymphomas and Hematological Malignancies

In cases of suspected lymphoma, a 7-IHC panel is critical for distinguishing between Hodgkin and non-Hodgkin lymphomas, as well as subtyping B-cell and T-cell malignancies. Because different subtypes of lymphoma require vastly different chemotherapeutic regimens, precise classification is vital. The panel evaluates specific cluster of differentiation (CD) markers, such as CD3, CD20, CD30, CD15, and proliferation markers like Ki-67, to establish a definitive immunophenotypic profile.

Breast Cancer Biomarker Profiling

For patients diagnosed with breast carcinoma, the 7-IHC panel is routinely performed to evaluate prognostic and predictive biomarkers. This panel typically includes Estrogen Receptor (ER), Progesterone Receptor (PR), Human Epidermal Growth Factor Receptor 2 (HER2), and Ki-67, along with basal or myoepithelial markers. The results directly determine whether the patient will benefit from targeted endocrine therapies, anti-HER2 monoclonal antibodies, or aggressive chemotherapy regimens.

Identification of Metastatic Cancer of Unknown Primary (CUP)

When a patient presents with metastatic disease in an organ such as the liver, lung, bone, or lymph nodes, but the primary site of the tumor is unknown, a 7-IHC panel is employed to trace the tissue of origin. By selecting organ-specific transcription factors and cytokeratin profiles (such as CK7, CK20, TTF-1, CDX2, and GATA3), pathologists can pinpoint the primary source of the malignancy, allowing oncologists to initiate site-specific systemic therapy.

Prognostic and Predictive Assessment in Oncology

Beyond diagnosis, the 7-IHC panel is performed to assess the biological behavior of a tumor and its likelihood of responding to specific therapies. Markers that evaluate cell cycle progression, tumor suppressor gene expression (such as p53), mismatch repair protein status (dMMR), or immune checkpoint expression (such as PD-L1) provide invaluable prognostic information, helping clinicians estimate overall survival and disease-free survival intervals.

What Does a IMMUNOHISTOCHEMISTRY PANEL (7-IHC) Detect?

The IMMUNOHISTOCHEMISTRY PANEL (7-IHC) at Test Zone Diagnostic Center is capable of detecting a wide array of cellular proteins, transcription factors, and cell surface receptors. Depending on the clinical indication, the panel can be configured to detect and evaluate:

• Cytokeratin AE1/AE3: A broad-spectrum epithelial marker used to confirm carcinoma.
• Cytokeratin 7 (CK7): Expressed in epithelial cells of the lung, breast, thyroid, and upper gastrointestinal tract.
• Cytokeratin 20 (CK20): Primarily expressed in epithelial cells of the colon, rectum, and Merkel cell carcinoma.
• Vimentin: A major intermediate filament of mesenchymal cells, positive in sarcomas and some carcinomas.
• Leukocyte Common Antigen (LCA / CD45): A definitive marker for hematolymphoid cells, distinguishing lymphomas from carcinomas.
• S100 Protein: Highly sensitive for cells of neural crest origin, including melanomas and schwannomas.
• Melan-A / MART-1: A highly specific marker for melanocytic differentiation.
• SOX10: A nuclear transcription factor crucial for diagnosing spindle cell and desmoplastic melanomas.
• Thyroid Transcription Factor-1 (TTF-1): Positive in primary lung adenocarcinomas and thyroid neoplasms.
• p40 / p63: Nuclear markers highly specific for squamous cell differentiation.
• CD20: A cell surface marker expressed on mature B-lymphocytes.
• CD3: A lineage-specific T-cell marker utilized in lymphoma subtyping.
• CD30: Expressed on Reed-Sternberg cells in Hodgkin lymphoma and anaplastic large cell lymphomas.
• CD15: Used in conjunction with CD30 to confirm classical Hodgkin lymphoma.
• Estrogen Receptor (ER): Evaluates hormone receptor status in breast and gynecological malignancies.
• Progesterone Receptor (PR): Assesses progesterone receptor expression for therapeutic planning.
• HER2/neu: Evaluates oncogene amplification/overexpression in breast and gastric cancers.
• Ki-67: A nuclear marker that measures the cellular proliferation index of the tumor.
• Synaptophysin: A membrane glycoprotein indicative of neuroendocrine differentiation.
• Chromogranin A: An acidic glycoprotein found in secretory granules of neuroendocrine cells.
• CD56 (NCAM): A neural cell adhesion molecule used to identify neuroendocrine tumors and NK-cell malignancies.
• Calretinin: A calcium-binding protein highly specific for mesothelial cells, aiding in the diagnosis of mesothelioma.
• WT1 (Wilms Tumor 1): Expressed in mesotheliomas and ovarian serous carcinomas.
• GATA3: A transcription factor highly sensitive for breast and urothelial carcinomas.
• Pax-8: A nuclear marker for renal, thyroid, and Müllerian tumors.
• CD117 (c-KIT): Diagnostic marker for gastrointestinal stromal tumors (GIST) and mast cell diseases.
• Desmin: An intermediate filament protein specific to smooth and skeletal muscle differentiation.
• Smooth Muscle Actin (SMA): Identifies smooth muscle tumors and myoepithelial cells in breast lesions.

Turnaround Time and Report Access at Test Zone Diagnostic Center

At Test Zone Diagnostic Center, we understand that waiting for pathology results can be an anxious time for patients and their families. Because the IMMUNOHISTOCHEMISTRY PANEL (7-IHC) involves complex, multi-stage laboratory processing, antigen retrieval, antibody incubation, and detailed microscopic analysis by a consultant pathologist, the turnaround time is typically longer than routine blood tests. Generally, the final verified report is available within 3 to 5 working days from the receipt of the tissue specimen or paraffin block. Test Zone Diagnostic Center utilizes an advanced Laboratory Information Management System (LIMS) to ensure absolute specimen tracking and quality control at every stage. Once the report is finalized and signed off by the reporting pathologist, patients receive an automated SMS notification. Reports can be accessed securely online via the official Test Zone Diagnostic Center web portal or mobile application, or collected in person from our main diagnostic facility.

IMMUNOHISTOCHEMISTRY PANEL (7-IHC) Findings Overview

The following table outlines some of the primary markers evaluated in a typical 7-IHC panel, along with their expected normal and abnormal expression patterns:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Epithelial Markers (e.g., CK AE1/AE3)	Negative in non-epithelial tissues	Strong cytoplasmic positivity indicating carcinoma or epithelial differentiation
Lymphoid Markers (e.g., LCA / CD45)	Positive only in normal inflammatory/lymphoid cells	Diffuse positivity in tumor cells indicating lymphoma or leukemia
Melanocytic Markers (e.g., S100, Melan-A)	Negative in epithelial and mesenchymal tissues	Strong cytoplasmic and nuclear positivity indicating malignant melanoma
Hormone Receptors (e.g., ER / PR)	Variable expression in normal breast/uterine tissue	Overexpression in breast carcinoma, guiding endocrine therapy selection
Oncoprotein Expression (e.g., HER2)	Negative or weak membranous expression (0 or 1+)	Strong, complete membranous expression (3+) indicating HER2-positive malignancy
Proliferation Index (Ki-67)	Low expression in resting/benign tissues (<5%)	Elevated expression (>20% to 90%) indicating highly aggressive, rapidly dividing tumor cells
Neuroendocrine Markers (e.g., Synaptophysin)	Negative in non-neuroendocrine tissues	Diffuse cytoplasmic positivity indicating neuroendocrine tumor or small cell carcinoma
Myoepithelial Markers (e.g., p63, SMA)	Intact, continuous layer around normal breast ducts	Loss of myoepithelial layer indicating invasive breast carcinoma

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Test Zone Diagnostic Center for IMMUNOHISTOCHEMISTRY PANEL (7-IHC)?

• Experienced Healthcare Professionals: Our pathology department is led by highly qualified, board-certified consultant histopathologists with extensive experience in oncological pathology.
• Patient-Focused Care: We prioritize patient well-being, ensuring that tissue specimens are handled with the utmost care, respect, and clinical urgency.
• Quality Diagnostic Services: Test Zone Diagnostic Center adheres to strict internal and external quality assurance protocols to guarantee the reproducibility and accuracy of every IHC stain.
• Professional Reporting: Our reports provide comprehensive, detailed immunophenotypic descriptions, including semi-quantitative scoring and high-resolution digital imaging references when required.
• Modern Diagnostic Approach: We utilize state-of-the-art automated staining platforms that minimize human error, optimize antibody consumption, and ensure consistent staining quality.
• Comfortable Environment: Our diagnostic center offers a welcoming, professional, and patient-friendly atmosphere for specimen submission and consultation.
• Convenient Location: Located centrally with easy accessibility, making it convenient for patients to submit blocks, slides, or biopsy specimens.
• Commitment to Accurate Diagnosis: We understand that an accurate IHC profile is critical for cancer staging and treatment, and we are committed to delivering precise, evidence-based diagnostic insights.